Bausch Health Companies Inc. (TSE:BHC – Free Report) – Research analysts at Zacks Research dropped their Q2 2027 earnings per share estimates for shares of Bausch Health Companies in a report issued on Monday, July 27th. Zacks Research analyst Team now forecasts that the company will earn $1.15 per share for the quarter, down from their previous estimate of $1.16. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q3 2027 earnings at $1.46 EPS, Q4 2027 earnings at $1.32 EPS, FY2027 earnings at $5.06 EPS, Q2 2028 earnings at $1.14 EPS and FY2028 earnings at $4.26 EPS.
Bausch Health Companies (TSE:BHC – Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The company reported C$1.08 earnings per share for the quarter. Bausch Health Companies had a positive return on equity of 120.43% and a negative net margin of 13.54%.The firm had revenue of C$3.51 billion during the quarter.
Read Our Latest Stock Report on Bausch Health Companies
Bausch Health Companies Trading Up 0.9%
Shares of TSE:BHC opened at C$6.40 on Wednesday. The business’s 50-day moving average is C$6.98 and its 200 day moving average is C$7.60. Bausch Health Companies has a 1 year low of C$6.10 and a 1 year high of C$11.97. The firm has a market capitalization of C$2.39 billion, a P/E ratio of -1.98, a P/E/G ratio of 0.21 and a beta of 0.97. The company has a debt-to-equity ratio of -1,009.96, a current ratio of 1.32 and a quick ratio of 0.58.
Trending Headlines about Bausch Health Companies
Here are the key news stories impacting Bausch Health Companies this week:
- Positive Sentiment: Alberta’s public drug plan will reimburse eligible patients for Bausch Health’s Elidel (pimecrolimus) cream for mild-to-moderate atopic dermatitis. The expanded coverage could improve patient access and support demand for the dermatology product. Elidel Reimbursement Under Alberta Public Drug Plan
- Neutral Sentiment: Zacks Research’s July 24 revisions were broadly favorable, including higher estimates for third-quarter 2026 EPS of $1.47, fiscal 2027 EPS of $5.10 and fiscal 2028 EPS of $4.34. However, these projections were subsequently revised lower in the firm’s July 27 updates.
- Negative Sentiment: The latest Zacks forecasts reduced EPS expectations for several periods: Q2 2027 to $1.15 from $1.16, Q3 2027 to $1.46 from $1.47, Q4 2027 to $1.32 from $1.33, fiscal 2027 to $5.06 from $5.10, Q2 2028 to $1.14 from $1.16 and fiscal 2028 to $4.26 from $4.34. The cuts indicate modestly weaker expected earnings momentum and may limit upside for BHC.
- Negative Sentiment: The latest fiscal 2028 estimate of $4.26 is also below the current-year consensus EPS estimate of $5.55, highlighting expectations for earnings contraction beyond the current year.
About Bausch Health Companies
Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.
Featured Stories
- Five stocks we like better than Bausch Health Companies
- D-Wave’s AT&T Deal Shows Quantum Computing Is Moving Beyond Theory
- Insiders Sell, Institutions Buy: The AI Trade Is Getting More Interesting
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.
